Filtered By:
Specialty: Cardiology
Drug: Amiodarone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study
ConclusionThe study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
Source: Cardiovascular Drugs and Therapy - December 17, 2022 Category: Cardiology Source Type: research
Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis
ConclusionThe benefit-risk profile of NOACs compared to VKAs was preserved in AF patients using P-gp/CYP3A4 inhibitors, including amiodarone.
Source: Cardiovascular Drugs and Therapy - October 12, 2021 Category: Cardiology Source Type: research
Main determinants of physician-driven amiodarone discontinuation in clinical practice
ConclusionStudy showed that within the first two years of treatment, despite persistent indication, amiodarone was discontinued in 1 out of 10 patients in the absence of side effects, mostly in younger patients with less comorbidities, which may not always be justified. There is a need for qualitative research to elucidate the reasons for such physicians ’ decisions. Table.Multivariable Cox Proportional HAZARD Regression analysis of permanent Amiodarone discontinuation due to physician decisionVariableHR95% CIP valueAge0.9700.95-0.990.003VT/VF/electrical storm0.1390.04-0.450.001VKA therapy0.5980.38-0.940.026Ablation of A...
Source: Europace - May 24, 2021 Category: Cardiology Source Type: research
Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer
A 76-year-old female with obesity, hypertension, persistent atrial fibrillation, and heart failure with preserved ejection fraction is started on ibrutinib 420 mg once daily for Waldenstrom ’s macroglobulinemia. Due to concern for drug-drug interactions, her amiodarone is decreased from 200 to 100 mg daily, and she is continued on metoprolol succinate 100 mg daily and apixaban 5 mg twice daily. She presents to the clinic one month later with extensive superficial ecchymoses, and her apixaban dose is reduced to 2.5 mg twice daily due to concerns that this may reflect the combined antiplatelet effects of ibrutinib and anti...
Source: Heart Rhythm - April 27, 2021 Category: Cardiology Authors: Shiv Bagga, Sourbha S. Dani, Bruce G. Hook, Anju Nohria, Sarju Ganatra Source Type: research
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management
Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM patients are 27.09%. Higher risk of death noted in HCM patients with atrial fibrillation. Stroke and other thrombo embolic risks are increased in such patients. Medical management using mainly betablockers or amiodarone produced variable results and high rate of recurrence. Catheter ablation reduced symptom burden and complications despite moderate recurrence. Patients wi...
Source: Critical Pathways in Cardiology - May 16, 2020 Category: Cardiology Tags: Review Article Source Type: research
Patterns of Amiodarone use and outcomes in clinical practice for atrial fibrillation
ConclusionsUse of amiodarone among AF patients in community practice is highly variable. More than 2 out of 3 patients treated with amiodarone appeared to be eligible for a different AAD.
Source: American Heart Journal - October 24, 2019 Category: Cardiology Source Type: research
Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
CONCLUSIONS: NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors.
SYSTEMATIC REVIEW REGISTRATION: The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808).
PMID: 30770140 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 12, 2019 Category: Cardiology Authors: Kim IS, Kim HJ, Yu HT, Kim TH, Uhm JS, Kim JY, Joung B, Lee MH, Pak HN Tags: J Cardiol Source Type: research
Apples will never be oranges, but when you go fishing you may get a bite
Dronedarone is the newest available oral antiarrhythmic drug (AAD). In a paper by Ehrlich et al. [1] accompanying this editorial the authors report on risks for myocardial infarction (MI) and stroke in AF patients given a first prescription for dronedarone, amiodarone, flecainide, propafenone, or sotalol in 1258 general and 62 cardiology practices between January 2010 and March 2017. They attempt to compare MI and stroke risks in dronedarone patients (n = 3498) versus those treated with all the other stated antiarrhythmic drugs (AAD) analyzed in combination (n = 17,724).
Source: International Journal of Cardiology - December 13, 2018 Category: Cardiology Authors: James A. Reiffel Tags: Editorial Source Type: research
Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients
ConclusionA significant number of patients received NOACs at doses inconsistent with the package labeling or had clinically significant drug –drug interactions with NOACs. Efforts are warranted to improve appropriate dosing and avoid significant drug interactions.
Source: American Journal of Cardiovascular Drugs - November 8, 2018 Category: Cardiology Source Type: research
Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin
ConclusionAmong patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.
Source: Journal of Interventional Cardiac Electrophysiology - August 20, 2018 Category: Cardiology Source Type: research
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Conclusions -Transient symptomatic episodes of AF, although relatively uncommon in HCM, are unpredictable in frequency and timing, amenable to effective contemporary treatments, and infrequently progress to permanent AF. AF is not a major contributor to heart failure morbidity, nor a cause of arrhythmic sudden death, and when treated is associated with low-disease-related mortality, no different than for patients without AF. AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy.
PMID: 28916640 [PubMed - as supplied by publisher]
Source: Circulation - September 15, 2017 Category: Cardiology Authors: Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ Tags: Circulation Source Type: research
Management of New ‐Onset Postoperative Atrial Fibrillation Utilizing Insertable Cardiac Monitor Technology to Observe Recurrence of AF
Conclusion: POAF may represent a propensity for recurrent PAF, and not simply a transient consequence of post‐operative stress and inflammation. Better detection of recurrent AF might identify patients at risk for stroke who would benefit from continuing anticoagulation.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - July 31, 2016 Category: Cardiology Authors: MIKHAEL F. EL ‐CHAMI, FAISAL M MERCHANT, PAIGE SMITH, MATHEW LEVY, ANGELA GILL NELMS, JOHN MERLINO, JOHN PUSKAS, ANGEL R. LEON Tags: ELECTROPHYSIOLOGY Source Type: research
Pulmonary Hypertension due to Radiofrequency Catheter Ablation (RFCA) for Atrial Fibrillation: The Lungs, the Atrium or the Ventricle?
Atrial fibrillation is the most common heart rhythm disorder affecting around 2.5 million people in United States. It is characterised by rapid and irregular beating of both the atria resulting in the similar ventricular response. It is associated with the risk of stroke and heart failure resulting in increased morbidity and mortality [1]. The treatment of atrial fibrillation involves rate control with ant-arrhythmic drugs like beta blockers, digoxin and amiodarone. Cardioversion is recommended in case of haemodynamic instability or after failure of pharmacological therapies.
Source: Heart, Lung and Circulation - July 15, 2016 Category: Cardiology Authors: Isha Verma, Hemantkumar Tripathi, Rutuja Rajanikant Sikachi, Abhinav Agrawal Tags: Review Source Type: research
Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy.
CONCLUSION: In patients with rheumatic MS and AF, early DCCV and a short-duration oral Amiodarone, following successful PBMV, may be a reasonable strategy to attain long-term SR.
PMID: 27543470 [PubMed - in process]
Source: Indian Heart J - June 30, 2016 Category: Cardiology Authors: Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, Juneja R, Kalaivani M, Bahl VK Tags: Indian Heart J Source Type: research
